Dianthus Therapeutics’ (DNTH) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a report released on Wednesday morning,Benzinga reports. The firm currently has a $40.00 target price on the stock.

A number of other analysts have also weighed in on DNTH. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. TD Cowen assumed coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating for the company. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $52.14.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock opened at $21.90 on Wednesday. The stock has a fifty day moving average price of $22.65 and a two-hundred day moving average price of $24.94. Dianthus Therapeutics has a 52-week low of $18.13 and a 52-week high of $33.77. The firm has a market capitalization of $648.17 million, a P/E ratio of -8.76 and a beta of 1.82.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. On average, equities research analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Several hedge funds have recently added to or reduced their stakes in DNTH. R Squared Ltd bought a new position in Dianthus Therapeutics in the fourth quarter valued at about $26,000. Quest Partners LLC boosted its holdings in Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in Dianthus Therapeutics in the fourth quarter valued at about $33,000. KBC Group NV bought a new position in Dianthus Therapeutics during the fourth quarter worth about $35,000. Finally, BNP Paribas Financial Markets bought a new position in Dianthus Therapeutics during the fourth quarter worth about $59,000. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.